| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Obinutuzumab (Gazyva) | 2025-12-01 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Oncologic Indications for Histone Deacetylase (HDAC) Inhibitors | 2025-12-01 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Golimumab (Simponi, Simponi Aria) | 2025-12-01 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Glofitamab-gxbm (Columvi) | 2025-12-01 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Human Growth Hormone | 2025-12-01 |
| BCBS Highmark Penn Medicare Advantage | Glofitamab-gxbm (Columvi) | 2025-12-01 |
| BCBS Highmark Penn Medicare Advantage | Evinacumab-dgnb (Evkeeza) | 2025-12-01 |
| BCBS Highmark Penn Medicare Advantage | Oncologic indications for Histone deacetylase (HDAC) inhibitors | 2025-12-01 |
| BCBS Highmark Penn Medicare Advantage | Complement Inhibitors | 2025-12-01 |
| BCBS Highmark NY and West NY | Nerve Conduction Studies and Electromyography | 2025-12-01 |